In 2022, Pfizer has put capital to work as we strive to fuel future growth and return cash dividends directly to investors. In the first six months of 2022, the company re-invested more than $12 billion in total into innovation, consisting of $5.1 billion in its R&D innovation pipeline and more than $7 billion in […]
Read the full article here
